Short answer
Disc Medicine, Inc. (IRON) filed its Q1 2026 10-Q quarterly report on May 5, 2026 for the quarter ended Mar 31, 2026.
Q1 2026 key financials · XBRL
- Net income
- −$64M
- −86.3% YoY
- EPS (diluted)
- −$1.65
- −61.8% YoY
Source: XBRL data from the Disc Medicine, Inc. (IRON) Q1 2026 10-Q on SEC EDGAR. USD.
Disc Medicine, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, unchanged year over year, with no product sales since inception
- Operating margin not meaningful; operating loss $69.5M vs $39.9M YoY
- DISC-3405 R&D $9.2M, up $7.5M; bitopertin R&D $9.3M, up $0.9M
- Cash, equivalents and securities $730.2M; operating cash use $62.2M vs $41.4M YoY
- APOLLO enrollment complete at 183; topline data expected Q4 2026, NDA decision anticipated mid-2027
Risk Factors
- Net losses $63.5 million in Q1 2026 versus $34.1 million in Q1 2025, increasing funding pressure
- Hercules term loan up to $200.0 million matures December 1, 2029, with qualified-cash covenant and secured collateral
- FDA may require additional clinical trials or stricter approval conditions, delaying or preventing product commercialization
- Three product candidates remain in clinical development, with none completing Phase 3 trials
- Up to $80.0 million of additional 2026 debt advances available, but no other committed external funding source
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Disc Medicine, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.